Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
40 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Renal Insufficiency - Pipeline Review, H1 2016 Summary
Global Markets Direct's, 'Renal Insufficiency - Pipeline Review, H1 2016', provides an overview of the Renal Insufficiency pipeline landscape. The report provides comprehensive information on the therapeutics under development for Renal Insufficiency, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Renal Insufficiency and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Renal Insufficiency - The report reviews pipeline therapeutics for Renal Insufficiency by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Renal Insufficiency therapeutics and enlists all their major and minor projects - The report assesses Renal Insufficiency therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Renal Insufficiency Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Renal Insufficiency - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Renal Insufficiency pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Renal Insufficiency Overview 6 Therapeutics Development 7 Pipeline Products for Renal Insufficiency - Overview 7 Renal Insufficiency - Therapeutics under Development by Companies 8 Renal Insufficiency - Pipeline Products Glance 9 Clinical Stage Products 9 Renal Insufficiency - Products under Development by Companies 10 Renal Insufficiency - Companies Involved in Therapeutics Development 11 Elcelyx Therapeutics, Inc. 11 Nippon Zoki Pharmaceutical Co., Ltd. 12 Novartis AG 13 The Medicines Company 14 Renal Insufficiency - Therapeutics Assessment 15 Assessment by Monotherapy Products 15 Assessment by Combination Products 16 Assessment by Target 17 Assessment by Mechanism of Action 19 Assessment by Route of Administration 21 Assessment by Molecule Type 23 Drug Profiles 25 (meropenem+ RPX-7009) - Drug Profile 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 BHQ-880 - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 LHW-090 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 metformin hydrochloride DR - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 NZ-419 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Renal Insufficiency - Recent Pipeline Updates 34 Renal Insufficiency - Dormant Projects 37 Renal Insufficiency - Discontinued Products 38 Appendix 39 Methodology 39 Coverage 39 Secondary Research 39 Primary Research 39 Expert Panel Validation 39 Contact Us 39 Disclaimer 40
List of Tables
Number of Products under Development for Renal Insufficiency, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Clinical Stage Development, H1 2016 9 Products under Development by Companies, H1 2016 10 Renal Insufficiency - Pipeline by Elcelyx Therapeutics, Inc., H1 2016 11 Renal Insufficiency - Pipeline by Nippon Zoki Pharmaceutical Co., Ltd., H1 2016 12 Renal Insufficiency - Pipeline by Novartis AG, H1 2016 13 Renal Insufficiency - Pipeline by The Medicines Company, H1 2016 14 Assessment by Monotherapy Products, H1 2016 15 Assessment by Combination Products, H1 2016 16 Number of Products by Stage and Target, H1 2016 18 Number of Products by Stage and Mechanism of Action, H1 2016 20 Number of Products by Stage and Route of Administration, H1 2016 22 Number of Products by Stage and Molecule Type, H1 2016 24 Renal Insufficiency Therapeutics - Recent Pipeline Updates, H1 2016 34 Renal Insufficiency - Dormant Projects, H1 2016 37 Renal Insufficiency - Discontinued Products, H1 2016 38
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.